---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-286273"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-06-26T22:18:31+00:00"
generated_at: "2026-06-29T10:05:45.442250+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics receives FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease

## Summary
- Lumvoa is the first FDA-approved treatment for TED with labeling covering both active and chronic disease.
- Approval supported by positive Phase 3 THRIVE and THRIVE-2 trials meeting primary and all secondary endpoints.
- Lumvoa showed statistically significant improvement in diplopia response and complete resolution in active and chronic TED.
- Viridian plans to launch Lumvoa immediately with a comprehensive patient support program (ViridianCares).
- Company will host a conference call on June 29, 2026, at 8:00 a.m. ET to discuss the approval.

## SEC filing metadata
- accession: 0001193125-26-286273
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-06-26T22:18:31+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/0001193125-26-286273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-286273
- JSON: https://secwatch.observer/filing/0001193125-26-286273.json
- Plain text: https://secwatch.observer/filing/0001193125-26-286273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.